H-REV107-1 stimulates growth in non-small cell lung carcinomas via the activation of mitogenic signaling

American Journal of Pathology

Volumn 169, Issue 4, 2006, Pages 1427-1439

  Nazarenko, Irina ^a   Kristiansen, Glen ^a   Fonfara, Sabine ^a   Guenther, Raphaela ^a   Gieseler, Cornelia ^a   Kemmner, Wolfgang ^b   Schafer, Reinhold ^a   Petersen, Iver ^a   Sers, Christine ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; ONCOPROTEIN; PROTEIN H REV107 1; RAS PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; HRASLS3 PROTEIN, HUMAN; SIGNAL PEPTIDE; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; CELL CULTURE; CHEMISTRY; DRUG ANTAGONISM; ENZYME ACTIVATION; IMMUNOHISTOCHEMISTRY; INTRACELLULAR MEMBRANE; LUNG TUMOR; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; TRANSACTIVATION;

CARCINOMA, NON-SMALL-CELL LUNG; ENZYME ACTIVATION; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR MEMBRANES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROGNOSIS; RAS PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS); TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 38849195406     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2006.051341     Document Type: Article

References (55)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ: Cancer statistics, 2003. CA Cancer J Clin 2003, 53:5-26
2. Fong KM, Sekido Y, Gazdar AF, Minna JD: Lung cancer-9: molecular biology of lung cancer: clinical implications. Thorax 2003, 58:892-900
3. Huang SL, Shyu RY, Yeh MY, Jiang SY: Cloning and characterization of a novel retinoid-inducible gene 1(RIG1) deriving from human gastric cancer cells. Mol Cell Endocrinol 2000, 159:15-24
4. Seftor RE, Seftor EA, Sheng S, Pemberton PA, Sager R, Hendrix MJ: Maspin suppresses the invasive phenotype of human breast carcinoma. Cancer Res 1998, 58:5681-5685
5. Sers C, Husmann K, Nazarenko I, Reich S, Wiechen K, Zhumabayeva B, Adhikari P, Schroder K, Gontarewicz A, Schafer R: The class II tumour suppressor gene H-REV107-1 is a target of interferon-regulatory factor-1 and is involved in IFNgamma-induced cell death in human ovarian carcinoma cells. Oncogene 2002, 21:2829-2839
6. Zhang M, Maass N, Magit D, Sager R: Transactivation through Ets and Ap1 transcription sites determines the expression of the tumor-suppressing gene maspin. Cell Growth Differ 1997, 8:179-186
7. Wiechen K, Diatchenko L, Agoulnik A, Scharff KM, Schober H, Arlt K, Zhumabayeva B, Siebert PD, Dietel M, Schafer R, Sers C: Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol 2001, 159:1635-1643
8. Belanger MM, Roussel E, Couet J: Caveolin-1 is down-regulated in human lung carcinoma and acts as a candidate tumor suppressor gene. Chest 2004, 125:106S
9. Sagara Y, Mimori K, Yoshinaga K, Tanaka F, Nishida K, Ohno S, Inoue H, Mori M: Clinical significance of caveolin-1, caveolin-2 and HER2/ neu mRNA expression in human breast cancer. Br J Cancer 2004, 91:959-965
10. Sunaga N, Miyajima K, Suzuki M, Sato M, White MA, Ramirez RD, Shay JW, Gazdar AF, Minna JD: Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Res 2004, 64:4277-4285
11. Hughes PJ, Stanway G: The 2A proteins of three diverse picornaviruses are related to each other and to the H-rev107 family of proteins involved in the control of cell proliferation. J Gen Virol 2000, 81:201-207
12. Anantharaman V, Aravind L: Evolutionary history, structural features and biochemical diversity of the NlpC/P60 superfamily of enzymes. Genome Biol 2003, 4:R11
13. Kaneda A, Kaminishi M, Yanagihara K, Sugimura T, Ushijima T: Identification of silencing of nine genes in human gastric cancers. Cancer Res 2002, 62:6645-6650
14. Roder K, Latasa MJ, Sul HS: Silencing of the mouse H-rev107 gene encoding a class II tumor suppressor by CpG methylation. J Biol Chem 2002, 277:30543-30550
15. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC: World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Lung, Pleura Thymus and Heart. Lyon, IARC Press, 2004
16. Kallioniemi OP, Wagner U, Kononen J, Sauter G: Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001, 10:657-662
17. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A: Rational siRNA design for RNA interference. Nat Biotechnol 2004, 22:326-330
18. Wessel D, Flugge UI: A method for the quantitative recovery of protein in dilute-solution in the presence of detergents and lipids. Anal Biochem 1984, 138:141-143
19. Husmann K, Sers C, Fietze E, Mincheva A, Lichter P, Schafer R: Transcriptional and translational downregulation of H-REV107, a class II tumour suppressor gene located on human chromosome 11q11hyphen]12. Oncogene 1998, 17:1305-1312
20. Sers C, Emmenegger U, Husmann K, Bucher K, Andres AC, Schafer R: Growth-inhibitory activity and downregulation of the class II tumor-suppressor gene H-rev107 in tumor cell lines and experimental tumors. J Cell Biol 1997, 136:935-944
21. Chan SK, Gullick WJ, Hill ME: Mutations of the epidermal growth factor receptor in non-small cell lung cancer - search and destroy. Eur J Cancer 2006, 42:17-23
22. Shigematsu H, Gazdar AF: Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006, 118:257-262
23. Sato M, Vaughan MB, Girard L, Peyton M, Lee W, Shames DS, Ramirez RD, Sunaga N, Gazdar AF, Shay JW, Minna JD: Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res 2006, 66:2116-2128
24. Haura EB, Zheng Z, Song L, Cantor A, Bepler G: Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res 2005, 11:8288-8294
25. Downward J: Targeting RAS signaling pathways in cancer therapy. Nat Rev Cancer 2003, 3:11-22
26. Mitchell CE, Belinsky SA, Lechner JF: Detection and quantitation of mutant K-ras codon 12 restriction fragments by capillary electrophoresis. Anal Biochem 1995, 224:148-153
27. Willumsen BM, Christensen A, Hubbert NL, Papageorge AG, Lowy DR: The p21 ras C-terminus is required for transformation and membrane association. Nature 1984, 310:583-586
28. Arozarena I, Matallanas D, Berciano MT, Sanz-Moreno V, Calvo F, Munoz MT, Egea G, Lafarga M, Crespo P: Activation of H-Ras in the endoplasmic reticulum by the RasGRF family guanine nucleotide exchange factors. Mol Cell Biol 2004, 24:1516-1530
29. Dudler T, Gelb MH: Palmitoylation of Ha-Ras facilitates membrane binding, activation of downstream effectors, and meiotic maturation in Xenopus oocytes. J Biol Chem 1996, 271:11541-11547
30. Casey PJ, Solski PA, Der CJ, Buss JE: p21ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci USA 1989, 86:8323-8327
31. Srivastava SK, Yuasa Y, Reynolds SH, Aaronson SA: Effects of two major activating lesions on the structure and conformation of human ras oncogene products. Proc Natl Acad Sci USA 1985, 82:38-42
32. Gadbut AP, Wu L, Tang D, Papageorge A, Watson JA, Galper JB: Induction of the cholesterol metabolic pathway regulates the farnesylation of RAS in embryonic chick heart cells: a new role for ras in regulating the expression of muscarinic receptors and G proteins. EMBO J 1997, 16:7250-7260
33. Yoo SH, Park YS, Kim HR, Sung SW, Kim JH, Shim YS, Lee SD, Choi YL, Kim MK, Chung DH: Expression of caveolin-1 is associated with poor prognosis of patients with squamous cell carcinoma of the lung. Lung Cancer 2003, 42:195-202
34. Kato T, Miyamoto M, Kato K, Cho Y, Itoh T, Morikawa T, Okushiba S, Kondo S, Ohbuchi T, Katoh H: Difference of caveolin-1 expression pattern in human lung neoplastic tissue. Atypical adenomatous hyperplasia, adenocarcinoma and squamous cell carcinoma. Cancer Lett 2004, 214:121-128
35. Wei Y, Yang X, Liu Q, Wilkins JA, Chapman HA: A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J Cell Biol 1999, 144:1285-1294
36. Li L, Ren CH, Tahir SA, Ren C, Thompson TC: Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol 2003, 23:9389-9404
37. Huang SL, Shyu RY, Yeh MY, Jiang SY: The retinoid-inducible gene I: effect on apoptosis and mitogen-activated kinase signal pathways. Anticancer Res 2002, 22:799-804
38. Latha K, Zhang W, Cella N, Shi HY, Zhang M: Maspin mediates increased tumor cell apoptosis upon induction of the mitochondrial permeability transition. Mol Cell Biol 2005, 25:1737-1748
39. Shi HY, Zhang W, Liang R, Abraham S, Kittrell FS, Medina D, Zhang M: Blocking tumor growth, invasion, and metastasis by maspin in a syngeneic breast cancer model. Cancer Res 2001, 61:6945-6951
40. Zhang M, Shi Y, Magit D, Furth PA, Sager R: Reduced mammary tumor progression in WAP-TAg/WAP-maspin bitransgenic mice. Oncogene 2000, 19:6053-6058
41. Bieche I, Girault I, Sabourin JC, Tozlu S, Driouch K, Vidaud M, Lidereau R: Prognostic value of maspin mRNA expression in ER alpha-positive postmenopausal breast carcinomas. Br J Cancer 2003, 88:863-870
42. Sloan EK, Stanley KL, Anderson RL: Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene 2004, 23:7893-7897
43. Shimizu E, Coxon A, Otterson GA, Steinberg SM, Kratzke RA, Kim YW, Fedorko J, Oie H, Johnson BE, Mulshine JL: RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene 1994, 9:2441-2448
44. Forgacs E, Biesterveld EJ, Sekido Y, Fong K, Muneer S, Wistuba II, Milchgrub S, Brezinschek R, Virmani A, Gazdar AF, Minna JD: Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene 1998, 17:1557-1565
45. Kohno T, Takahashi M, Manda R, Yokota J: Inactivation of the PTEN/ MMAC1/TEP1 gene in human lung cancers. Genes Chromosom Cancer 1998, 22:152-156
46. Sturniolo MT, Dashti SR, Deucher A, Rorke EA, Broome AM, Chandraratna RAS, Keepers T, Eckert RL: A novel tumor suppressor protein promotes keratinocyte terminal differentiation via activation of type I transglutaminase. J Biol Chem 2003, 278:48066-48073
47. Hong KU, Reynolds SD, Giangreco A, Hurley CM, Stripp BR: Clara cell secretory protein-expressing cells of the airway neuroepithelial body microenvironment include a label-retaining subset and are critical for epithelial renewal after progenitor cell depletion. Am J Respir Cell Mol Biol 2001, 24:671-681
48. Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S, Crowley D, Bronson RT, Jacks T: Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005, 121:823-835
49. Lieber M, Smith B, Szakal A, Nelson-Rees W, Todaro G: A continuous tumor-cell line from a human lung carcinoma with properties of type II alveolar epithelial cells. Int J Cancer 1976, 17:62-70
50. Hirai K, Koizumi K, Haraguchi S, Hirata T, Mikami I, Fukushima M, Yamagishi S, Kawashima T, Okada D, Shimizu K, Kawamoto M: Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer. Ann Thorac Surg 2005, 79:248-253
51. Lonardo F, Li X, Siddiq F, Singh R, Al Abbadi M, Pass HI, Sheng S: Maspin nuclear localization is linked to favorable morphological features in pulmonary adenocarcinoma. Lung Cancer 2006, 51:31-39
52. Sood AK, Fletcher MS, Gruman LM, Coffin JE, Jabbari S, Khalkhali-Ellis Z, Arbour N, Seftor EA, Hendrix MJ: The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res 2002, 8:2924-2932
53. Mohsin SK, Zhang M, Clark GM, Craig AD: Maspin expression in invasive breast cancer: association with other prognostic factors. J Pathol 2003, 199:432-435
54. Crook T, Parker GA, Rozycka M, Crossland S, Allday MJ: A transforming p53 mutant, which binds DNA, transactivates and induces apoptosis reveals a nuclear:cytoplasmic shuttling defect. Oncogene 1998, 16:1429-1441
55. Vicent S, Lopez-Picazo JM, Toledo G, Lozano MD, Torre W, Garcia-Corchon C, Quero C, Soria JC, Martin-Algarra S, Manzano RG, Montuenga LM: ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. Br J Cancer 2004, 90:1047-1052